Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (311-320 of 868) with videos related to

Pageof 87
Sort By:
Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
Cancer Research|April 17, 2002
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceSuzanne Lentzsch, Michael S Rogers, Richard LeBlanc, et al.
British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaPaul G Richardson, Ashraf Z Badros, Sundar Jagannath, et al.
The Journal of Pharmacy and Pharmacology|August 21, 2010
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivoTanyel Kiziltepe, Kenneth C Anderson, Jeffery L Kutok, et al.
Blood|June 26, 2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple MyelomaMorihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, et al.
Oncoimmunology|August 18, 2025
CyTOF profiling of bone marrow immune dynamics across myeloma stagesDana Cholujova, Gabor Beke, Lubos Klucar, et al.
Pageof 87

Showing results (311-320 of 868) with videos related to

Sort By:
Pageof 87
Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
Cancer Research|April 17, 2002
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceSuzanne Lentzsch, Michael S Rogers, Richard LeBlanc, et al.
British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaPaul G Richardson, Ashraf Z Badros, Sundar Jagannath, et al.
The Journal of Pharmacy and Pharmacology|August 21, 2010
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivoTanyel Kiziltepe, Kenneth C Anderson, Jeffery L Kutok, et al.
Blood|June 26, 2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple MyelomaMorihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, et al.
Oncoimmunology|August 18, 2025
CyTOF profiling of bone marrow immune dynamics across myeloma stagesDana Cholujova, Gabor Beke, Lubos Klucar, et al.
Pageof 87